An interventional study of Second-generation FARAWAVE Nav catheter without the use of pre-ablation CT and FARAPULSE with pre-ablation CT in Atrial Fibrillation (AF), Atrial Fibrillation Ablation and Pulsed Field Ablation, sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Cardiocentro Ticino · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Atrial Fibrillation with a site in Switzerland — 23 open to participants now, 33 under way, 1 of them phase 3. Atrial Fibrillation · Switzerland.
Among the 117 studies in Atrial Fibrillation with a site in Switzerland, this one is the 62nd largest by planned enrollment of the 70 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 with no phase, reaches primary completion later than 7 of the 32 other live ones, and was the 108th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →23 of the 117 studies in Atrial Fibrillation with a site in Switzerland are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Switzerland, Belgium, Germany and 3 more countries
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in Switzerland, United States, Australia and 3 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
University of L'Aquila · Sites in Switzerland, Croatia, Denmark and 12 more countries
Ages 18+
University Hospital, Geneva · Sites in Switzerland, Austria, Belgium and 11 more countries
Ages 60+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 19 · Phase 4 16
First in 2002; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 58 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 409 across the 70 interventional studies, 300 across the 46 observational. Of the 81 that completed or were terminated, 23 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 117 have an industry lead sponsor. The 10 most frequent:
Cardiocentro Ticino is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
Cardiocentro Ticino has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
7 of the studies in Atrial Fibrillation with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05890664Phase 3University Hospital, Basel, SwitzerlandColchicine After Electrocardioversion for Atrial Fibrillation | 2027-03 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
| NCT06808217Boston Scientific CorporationA Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation | 2027-04-01 |
| NCT04075084Biotronik SE & Co. KGObservation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs) | 2027-05-30 |
| NCT07852221Insel Gruppe AG, University Hospital BernPatient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 117 studies in Atrial Fibrillation with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow.
The FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps.
These features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure.
Our study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free survival
The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV) as standard of care for atrial fibrillation (AF) ablation. Several centers, including ours, utilize pre-procedural CT or cardiac magnetic resonance (CMR) imaging to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and both CT and CMR add significant logistical challenges to the procedural workflow.
The FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single device. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA System, including the creation of voltage and activation maps. Key technical enhancements of the FARAWAVE Nav PFA catheter include: Field Tag Technology: Field tagging estimates field volume and indicates energy delivery locations. Tags confirm overlap between applications, ensuring comprehensive PV isolation. Voltage/Activation Maps: Mapping data enhances procedure precision, allowing visualization of electrical activation and PV anatomy without reliance on pre-ablation CT imaging. These features address the limitations of the first-generation FARAPULSE catheter and have the potential to enhance procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may eliminate the need for pre-procedural CT or CMR, thereby reducing costs and minimizing patient exposure to radiation.
Our center, like several others, has used the first-generation catheter in routine clinical practice for over a year. More recently, we have also started using the second-generation catheter as part of standard clinical care. Currently, the two devices are used interchangeably, depending on logistical availability, particularly the presence of specialized technicians from Boston Scientific, who are required for the proper operation of the second-generation catheter.
Our study evaluates whether the FARAWAVE Nav catheter, without pre-ablation CT, allows to reduce fluoroscopy time and total patient radiation load as compared to conventional workflow with FARAPULSE catheter. Furthermore, procedural time, costs, number of PFA applications and AF recurrence free survival will be assessed.
Inclusion Criteria
Exclusion Criteria
Primary Endpoint
1. Fluoroscopy Time (measured in minutes)
Secondary Endpoints 2.1 Total Patient Radiation Load 2.2 Procedural Costs 2.3 Procedure Time 2.4 Left Atrial Dwelling Time 2.5 Fluoroscopy Time After Transseptal Puncture 2.6 Number of PFA Applications 2.7 AF Recurrence-Free Survival 2.8 AF Burden (in Patients with implantable loop recorder) 2.9 AF Burden (All Patients)
Randomization: 58 Patients will be randomized 1:1 to:
Intraprocedural fluoroscopy time will be collected at the time of AF ablation procedure.
To determine the required sample size for this study, we performed calculations based on previous studies, the expected fluoroscopy time are:
Control Group: Mean fluoroscopy time = 12 minutes, SD = 8 minutes [doi.org/10.1161/CIRCULATIONAHA.123.064959] Intervention Group: Mean fluoroscopy time = 7 minutes, SD = 7 minutes [doi:10.1161/CIRCEP.122.011780] Given these assumptions, that correspond to an effect size (Cohen'd) of 0.80, a power of 80% and a 2-sided alpha of 5%, we will need to enrol 52 patients (26 per group). To ensure the study remains adequately powered despite potential dropouts, protocol deviations, or missing data, an additional 10% buffer may be considered, bringing the total recommended enrolment to 58 patients per group. Calculations have been performed using the Stata software (release 18.5, StataCorp, College Station, TX, USA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FARAWAVE Nav without pre-ablation CT
Device: Second-generation FARAWAVE Nav catheter without the use of pre-ablation CT
FARAPULSE with pre-ablation CT
Device: FARAPULSE with pre-ablation CT
FARAWAVE Nav without pre-ablation CT (Intervention Group, n = 29) Description of the investigation-specific intervention: Participants in the intervention group will undergo pulmonary vein isolation (PVI) using the second-generation FARAWAVE Nav pulsed field ablation (PFA) catheter without the use of pre-ablation CT imaging. The FARAWAVE Nav catheter integrates magnetic navigation and electroanatomical mapping capabilities, allowing real-time visualization of left atrial anatomy and electrical signals. Energy delivery is based on non-thermal pulsed electric fields (irreversible electroporation), specifically targeting myocardial tissue while sparing surrounding structures.
FARAPULSE with pre-ablation CT (Control Group, n = 29) Description of the investigation-specific intervention: Participants in the control group will undergo pulmonary vein isolation (PVI) using the first-generation FARAPULSE pulsed field ablation (PFA) catheter. All patients in this group will undergo pre-procedural cardiac CT imaging to evaluate pulmonary vein anatomy and assist in procedural planning. The FARAPULSE catheter delivers non-thermal pulsed electric fields for selective myocardial ablation, aiming to achieve electrical isolation of the pulmonary veins.
Fluoroscopy time
The primary outcome of this investigation is fluoroscopy time, measured in minutes during the pulmonary vein isolation procedure. This outcome was chosen because it directly reflects the amount of radiation exposure experienced by the patient and is a critical measure of procedural efficiency and safety. For patients undergoing PVI plus additional left or right atrial ablations (planned or unplanned) the fluoroscopy time will be counted until the last application of the PVI. Fluoroscopic times will be compared between groups using the unpaired Student t test. The mean difference and 95%CI will be computed. In case of skewness, data will be log-transformed before entering the test. In this the mean difference on the log scale and the ratio on the original scale will be presented, both with 95%CI.
Time frame: immediately after the procedure
Total Patient Radiation Load
Total patient radiation load (cGy·cm²): to assess overall radiation exposure, including both imaging and intra-procedural sources. In case a patient randomized to the control group has already undergone a cardiac CT scan for another clinical reason in the past, the scan will not be repeated for ethical reasons. However, for the purpose of radiation dose calculation, the average radiation dose of a cardiac CT scan will be added as if the scan had been performed. Conversely, if a patient in the intervention group has previously undergone a cardiac CT scan, the operator will not review this scan prior to the procedure, and the corresponding radiation dose will not be included in the calculation. Analysis: same as the primary endpoint
Time frame: immediately after the procedure
Procedure Time
Procedure time (minutes): to evaluate procedural efficiency from catheter insertion to removal. For patients undergoing PVI plus additional left or right atrial ablations (planned or unplanned) the procedure time will be counted until the last application of the PVI. Analysis: same as the primary endpoint
Time frame: immediately after the procedure
Left Atrial Dwelling Time
Left atrial dwelling time (minutes): to assess the duration of catheter presence in the left atrium, which is associated with thromboembolic and procedural risks. Analysis: same as the primary endpoint.
Time frame: immediately after the procedure
Fluoroscopy Time After Transseptal Puncture
Fluoroscopy time after transseptal puncture (minutes): to determine radiation exposure specifically during the left atrial portion of the procedure.
Time frame: immediately after the procedure
Number of PFA Applications
Number of PFA applications: to evaluate treatment burden and procedural complexity.
Time frame: immediately after the procedure
AF Recurrence-Free Survival
AF Recurrence-Free Survival: Freedom from AF, atrial flutter, or atrial tachycardia lasting \>30 seconds, documented by ILR, over a 12-month follow-up, after two months of blanking period. Kaplan Meier event-free curves will be presented for each group and compared with the logrank test. Hazard ratios (HR) and 95%CI will be derived from a Cox model. Follow-up will start after the two months blanking period. Patients who die without atrial arrhythmia recurrence will be censored at the time of death
Time frame: up to 6 months
AF Burden
AF Burden: Proportion of time in AF, as assessed by the ILR over 6 months or 7 days Holter monitor. The same analysis as for the primary endpoint will be used.
Time frame: up to 6 months
Procedural Costs
Procedural costs: Pre-procedural imaging and procedural costs \[Cost of CT scan, FARAPULSE Catheter, FARAVEIW Catheter.\] The same analysis as for the primary endpoint will be used. In addition the ICER - incremental cost-effectiveness ratio - will be computes as the ratio of the difference in costs over the difference in effect as measures for the primary endpoint
Time frame: immediately after the procedure
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 9 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiocentro Ticino